3.42

0.58% -0.02

Arbutus Biopharma Corp (ABUS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$3.44

Aprire:

$3.46

Volume 24 ore:

951.21K

Relative Volume:

1.24

Capitalizzazione di mercato:

$645.63M

Reddito:

$12.99M

Utile/perdita netta:

$-74.39M

Rapporto P/E:

-7.7727

EPS:

-0.44

Flusso di cassa netto:

$-78.92M

1 W Prestazione:

+3.95%

1M Prestazione:

+6.54%

6M Prestazione:

-11.63%

1 anno Prestazione:

+18.75%

Intervallo 1D:

$3.40

$3.515

Intervallo di 1 settimana:

$3.3012

$3.515

Portata 52W:

$2.30

$4.725

Arbutus Biopharma Corp Stock (ABUS) Company Profile

Nome

Arbutus Biopharma Corp

Settore

Healthcare (1169)

Industria

Biotechnology (678)

Telefono

604-419-3200

Indirizzo

701 VETERANS CIRCLE, WARMINSTER, PA

Dipendente

Cinguettio

@arbutusbio

Prossima data di guadagno

2024-11-06

Ultimi documenti SEC

ABUS's Discussions on Twitter

Confronta ABUS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ABUS Arbutus Biopharma Corp	3.42	645.63M	12.99M	-74.39M	-78.92M	-0.44
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2022-02-02	Aggiornamento	Jefferies	Hold → Buy
2021-02-25	Iniziato	Jefferies	Hold
2020-12-17	Iniziato	H.C. Wainwright	Buy
2020-07-27	Ripresa	JMP Securities	Mkt Outperform
2020-07-24	Downgrade	Robert W. Baird	Outperform → Neutral
2020-05-19	Aggiornamento	Wedbush	Neutral → Outperform
2020-03-06	Aggiornamento	Chardan Capital Markets	Neutral → Buy
2020-02-20	Iniziato	Robert W. Baird	Outperform
2020-02-05	Aggiornamento	JMP Securities	Mkt Perform → Mkt Outperform
2019-10-07	Reiterato	B. Riley FBR	Buy
2019-10-04	Downgrade	Chardan Capital Markets	Buy → Neutral
2018-10-16	Aggiornamento	B. Riley FBR	Neutral → Buy
2018-10-15	Aggiornamento	Wedbush	Underperform → Neutral
2018-10-12	Reiterato	Chardan Capital Markets	Buy
2018-07-06	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
2018-03-19	Ripresa	Chardan Capital Markets	Buy
2018-03-19	Downgrade	Wedbush	Outperform → Neutral
2018-01-05	Iniziato	B. Riley FBR, Inc.	Buy
2017-04-04	Aggiornamento	Chardan Capital Markets	Neutral → Buy
2017-02-01	Reiterato	Wedbush	Outperform
2016-12-13	Downgrade	Chardan Capital Markets	Buy → Neutral
2016-11-30	Aggiornamento	Chardan Capital Markets	Neutral → Buy

Mostra tutto

Arbutus Biopharma Corp Borsa (ABUS) Ultime notizie

Feb 20, 2025

Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So. - The Motley Fool

Feb 20, 2025

Arbutus Biopharma's CFO David Hastings sells shares worth $72,826 - MSN

Feb 20, 2025

Feb 12, 2025

The Hidden Gem in Nasdaq’s Under $5 Club: Is Arbutus Biopharma the Next Big Thing? - Jomfruland.net

Feb 12, 2025

Is Arbutus Biopharma Corp. (ABUS) the Best Nasdaq Stock Under $5 to Buy? - Insider Monkey

Feb 12, 2025

Feb 11, 2025

Ebola Virus Vaccine Market May See a Big Move| Arbutus Biopharma, BioCryst Pharmaceuticals - openPR

Feb 11, 2025

Feb 08, 2025

SG Americas Securities LLC Purchases 16,250 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World

Feb 08, 2025

Feb 06, 2025